Cabometyx and Keytruda for renal cell carcinoma – pro
There is little literature on the cabozantinib pembrolizumab combination. More the half of patients with metastatic renal cell carcinoma (mRCC) who received pembrolizumab (Keytruda) in combination with cabozantinib (Cabometyx) had a response to the combination at the recommended phase 2 dose (RP2D) and tolerated treatment well, according to findings presented during the 2021 ASCO Annual Meeting.
More the half of patients with metastatic renal cell carcinoma who received pembrolizumab in combination with cabozantinib had a response to the combination at the recommended phase 2 dose and tolerated treatment well.
More the half of patients with metastatic renal cell carcinoma (mRCC) who received pembrolizumab (Keytruda) in combination with cabozantinib (Cabometyx) had a response to the combination at the recommended phase 2 dose (RP2D) and tolerated treatment well, according to findings presented during the 2021 ASCO Annual Meeting.
The phase 1/2 study met its primary endpoint. Among 40 evaluable patients, the objective response rate (ORR) was 63.2% (95% CI, 0.485-1.00), which included a partial response rate of 50% (n = 3 of 6) in patients with non-clear cell RCC. The clinical benefit rate was 97.4% (95% CI, 0.88-1.00).
Kessler ER, Hu J, Srivastava G, et al. Phase I/II study of pembrolizumab and cabozantinib for metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2021;39(suppl 15):4544. doi:10.1200/JCO.2021.39.15_suppl.4544
Tannir NM, Pal SK, Atkins MB. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. Oncologist. 2018 May;23(5):540-555.
Cabometyx Prescribing INformation 2022